Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merz Aesthetics, a new business unit of Merz Pharma Group, has launched Asclera (polidocanol) injection sclerotherapy treatment to doctors' offices throughout the US, which was initially available only in Europe.
Subscribe to our email newsletter
Merz Aesthetics said that Asclera was shown to be effective in treating sclerotherapy, in a study published in the June issue of Phlebology.
Merz Aesthetics’ Asclera was approved by the FDA to treat uncomplicated spider veins (varicose veins less than or equal to 1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremities. Once injected, it acts by damaging the cell lining of blood vessels, causing them to close and eventually disappear.
In the recent Phlebology study of Asclera, the authors found that the drug demonstrated efficacy over other treatment options, like sodium tetradecyl sulfate (STS) 1%.
Merz Aesthetics claimed that the treatment success rate for polidocanol was 95% at week 12 and 95% at week 26 vs. 92% and 91% for STS, respectively; both were higher than placebo.